ATRA - Company ID 0001604464
The table below shows Atara Biotherapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $120.77M | $128.94M | $8.57M | $63.57M | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $37.45M | $151.48M | $224.78M | $272.53M | $282.00M | $244.65M |
| SG&A |
Atara Biotherapeutics, Inc. reported annual revenue of $120.77M for fiscal year 2025. That is down 6.3% from $128.94M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $26.25M |
| $39.89M |
| $50.91M |
| $71.55M |
| $78.80M |
| $64.40M |
| Operating income | $35.86M | -$83.44M | -$276.01M | -$280.51M | -$340.46M | -$309.05M |
| Income tax | $31.00K | -$12.00K | $15.00K | $12.00K | $46.00K | $15.00K |
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M | -$340.14M | -$306.62M |
| EPS (diluted) | $2.57 | -$11.41 | -$65.19 | -$2.24 | -$3.63 | -$4.15 |